Read more about Prof. Ana Guerreiro Stücklin’s research here:
https://www.kispi.uzh.ch/kinderspital/person/guerreiro-stuecklin-md-phd-ana

Read more about Prof. Dr. Mitch Levesque’s research here:
https://www.usz.ch/en/clinic/comprehensive-cancer-center-zuerich/research/research-programs-groups/epigenetics-genetics-genomics-program/research-group-mitch-levesque/

Read more about Prof. Dr. med. Chantal Pauli's research here:
https://www.usz.ch/en/clinic/comprehensive-cancer-center-zuerich/research/research-programs-groups/epigenetics-genetics-genomics-program/research-group-chantal-pauli/

Read more about Dr. med. Dr. sc. nat. Tobias Weiss' research here:
https://www.usz.ch/fachbereich/neurologie/forschung/neuro-onkologie/

Malignant brain tumors are among the most challenging malignancies. My research group focuses on experimental and translational cancer research in the context of brain tumors, encompassing three main areas: 1. innovative cancer immunotherapies, 2. cutting-edge molecular and functional profiling technologies for precision oncology, and 3. multi-omic compatible liquid biopsy strategies. The ultimate goal of our research is to translate innovative approaches that we develop preclinically into clincal trials for patients to improve their care.

Read more about Dr. med. vet. Manuel Valiente's research here:
https://valientelab.com/

Manuel Valiente is the Head of the Brain Metastasis Group at CNIO (2015-present). He investigates the biology of brain metastasis in order to challenge this unmet clinical need using his background in Neuroscience (PhD, Instituto de Neurociencias, 2005-2009) and Cancer Biology (Postdoc, MSKCC, 2010-2014).
Specifically, his laboratory studies novel brain metastasis mediators, characterizes the metastasis-associated microenvironment, designs better experimental models and explores novel methods to target brain metastasis, including the frequent impact on
brain activity. All these aims consider the brain environment as a critical component to understand the biology of this progression of cancer.
Dr. Valiente has co-founded the first National Network of Brain Metastasis (RENACER) in Spain, which is allowing his team to speed up the translation of laboratory findings to the clinic. His contributions to brain metastasis research have been recognized with the Banco Sabadell Award, ASPIRE Award, ERC CoG, EMBO YIP, CLIP Award, Beug Foundation’s Prize for Metastasis Research, Bristol-Myers Squibb-MRA Young Investigator Award among others.
He is the Chair of the Scientific Committee of the European Association of Neuro-Oncology (EANO), Board Member of the Metastasis Research Society (MRS) and ESMO faculty member (CNS Tumours faculty group).